Clinical Trial Update: Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating low-dose fludarabine, busulfan, and anti-thymocyte globulin conditioning followed by donor umbilical cord blood transplant in patients …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndromes

Drugs mentioned

• BUSULFAN (Busulfan)
• Fludarabine (Fludarabine)
• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: University of California, San Francisco | Conditions: Leukemia, Lymphoma | Phase 1 | Status: COMPLETED